Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 15/20 | 0.73 |
| ▸ | HDAC3 | O15379 | 7/20 | 0.67 |
| ▸ | HDAC4 | P56524 | 7/20 | 0.67 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.67 |
| ▸ | HDAC7 | Q8WUI4 | 7/20 | 0.67 |
| ▸ | HDAC2 | Q92769 | 7/20 | 0.67 |
| ▸ | HDAC10 | Q969S8 | 7/20 | 0.67 |
| ▸ | HDAC11 | Q96DB2 | 7/20 | 0.67 |
| ▸ | HDAC8 | Q9BY41 | 7/20 | 0.67 |
| ▸ | HDAC6 | Q9UBN7 | 7/20 | 0.67 |
| ▸ | HDAC9 | Q9UKV0 | 7/20 | 0.67 |
| ▸ | HDAC5 | Q9UQL6 | 7/20 | 0.67 |
| ▸ | ERBB2 | P04626 | 6/20 | 0.66 |
| ▸ | GAK | O14976 | 2/20 | 0.65 |
| ▸ | FBP1 | P09467 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.63 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.63 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13514677 | 0.93 | EGFR (0.68) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13514686 | 0.92 | EGFR (0.66) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13514674 | 0.92 | EGFR (0.65) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| Epitinib SCHEMBL29409446 | 0.90 | EGFR (0.67) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| Epitinib SCHEMBL13514687 | 0.90 | EGFR (0.67) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13514688 | 0.90 | EGFR (0.67) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13514678 | 0.88 | EGFR (0.65) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13549112 | 0.88 | EGFR (0.63) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL13514680 | 0.88 | EGFR (0.66) | EGFRHDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL1766084 | 0.87 | EGFR (0.56) | EGFRHDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2318378-B1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2013-10-23 | — | — | EP | disclosed |
| EP-2318378-B1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTPR LTD (BS) | 2013-10-23 | — | — | EP | disclosed |
| US-20130217661-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-08-22 | — | — | US | disclosed |
| US-20130217661-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-08-22 | — | — | US | disclosed |
| US-8426430-B2 | Quinazoline derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-04-23 | — | — | US | disclosed |
| US-8426430-B2 | Quinazoline derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-04-23 | — | — | US | disclosed |
| US-8426430-B2 | Quinazoline derivatives | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2013-04-23 | — | — | US | disclosed |
| EP-2318378-A2 | QUINAZOLINE DERIVATIVES | Hutchison Medipharma Enterprises Limited (BS) | 2011-05-11 | — | — | EP | disclosed |
| US-20100009958-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-14 | — | — | US | disclosed |
| US-20100009958-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-14 | — | — | US | disclosed |
| US-20100009958-A1 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-14 | — | — | US | disclosed |
| WO-2010002845-A2 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010002845-A2 | QUINAZOLINE DERIVATIVES | HUTCHISON MEDIPHARMA ENTERPRISES LIMITED (BS) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100009958-A1 | QUINAZOLINE DERIVATIVES | NQO2, ABL1, RECQL | EGFR 1042/4885HDAC3 53/4885HDAC4 278/4885 |
| US-20130217661-A1 | QUINAZOLINE DERIVATIVES | NQO2, ABL1, RECQL | EGFR 1042/4885HDAC3 53/4885HDAC4 278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.